Sarcoma  >>  retaspimycin (IPI-504)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
retaspimycin (IPI-504) / Infinity Pharma
NCT00688766 / 2008-002396-28: Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

Terminated
3
47
US
retaspimycin hydrochloride (IPI-504), placebo, Best supportive care
Infinity Pharmaceuticals, Inc., MedImmune LLC, AstraZeneca
Gastrointestinal Stromal Tumors
05/09
05/09

Download Options